Recent Updates
Recently added Catalysts

Ad26.ZEBOV 5*10^10 viral particles

Phase 3

Healthy | Monoclonal antibody | Other |Johnson & Johnson|Last Updated: May 25, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment525
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02543567A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult ParticipantsPHASE3 COMPLETED 525Sep 21, 2015Nov 29, 2016May 25, 20256 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA)
At 21 days post boost vaccination

The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody

Secondary Endpoints
Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA)
At Days 1, 29, 57 post prime dose and at days 42, and 180 post boost vaccination
Number of Participants with Solicited Local and Systemic Adverse Events (AEs)
Up to 7 days after each vaccination
Number of Participants with Adverse Events (AEs)
Up to 42 days post boost vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group 1EXPERIMENTALAd26.ZEBOV 5\*10\^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1\*10\^8 Infectious Unit \[Inf. U.\] single dose IM injection on Day 57
Group 2EXPERIMENTALAd26.ZEBOV 2\*10\^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5\*10\^7 Inf. U single dose IM injection on Day 57
Group 3EXPERIMENTALAd26.ZEBOV 0.8\*10\^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5\*10\^7 Inf. U. single dose IM injection on Day 57
Group 4EXPERIMENTALParticipants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
Interventions
NameTypeDescription
Ad26.ZEBOV 5*10^10 viral particles (vp)BIOLOGICALAd26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
Ad26.ZEBOV 2*10^10 (vp)BIOLOGICALAd26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
Ad26.ZEBOV 0.8*10^10 (vp)BIOLOGICALAd26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]BIOLOGICALMVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
MVA-BN-Filo 5*10^7 Inf. U.BIOLOGICALMVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
PlaceboBIOLOGICALOne 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites6

Inclusion criteria : * Must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination, electrocardiogram (ECG) and vital signs performed at Screening * Must be healthy on the basis of clinical laboratory tests performed at Screening * Before randomizat...

Countries:United States
Unlock Eligibility Criteria